InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.42
(
0.47%
)
Bitcoin
62,667.55
(
-0.78%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 232992

Tuesday, 11/09/2021 1:18:52 PM

Tuesday, November 09, 2021 1:18:52 PM

Post# of 252311
Re: RVNC / VTRS Botox biosimilar

During yesterday’s VTRS 3Q21 CC, COO Rajiv Malik said VTRS and RVNC met with the FDA in Sep 2021 and obtained the FDA’s buy-in on the clinical data and analytics needed for an eventual 351(k) submission, which VTRS expects to occur in 2024. Malik further said that RVNC’s Daxi CRL will not affect the timing of the Botox-biosimilar program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up